Lethargic Depression Study

• Status: Completed
• Trial end date: 2005-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a study of Major Depressive Disorder (MDD) in patients with decreased energy, pleasure and interests.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Bupropion

Criteria

Inclusion criteria:

• Primary diagnosis of MDD with current duration lasting 12 weeks but no greater than 2 years.

• Generally in good health.

• Subject must read and write at a level sufficient to provide written informed consent.

Exclusion criteria:

• Current or past history of seizure disorder.

• Subject has a primary diagnosis or received treatment for panic disorder, obsessive compulsive disorder (OCD), post traumatic stress disorder (PTSD), acute stress disorder, Bipolar I or II disorder, schizophrenia, or other psychotic disorder.

• Currently using illicit drugs or other psychotropic drugs.

• Patient poses a current suicidal risk or has attempted suicide in the past 6 months.